Yarrow Bioscience, Inc. (YARW)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 8M 16M 24M Q3 '20: 16.8M Q4 '20: 21M Q1 '21: 19.5M Q2 '21: 8.1M Q3 '21: 4.9M Q4 '21: 931K Q1 '22: 879K Q2 '22: 710K Q3 '22: 744K Q4 '22: 477K Q1 '23: 398K Q2 '23: 407K Q3 '23: 354K Q4 '23: 424K Q1 '24: 423K Q2 '24: 486K Q3 '24: 493K Q4 '24: 501K Q1 '25: 605K Q2 '25: 476K Q4 '20 Q3 '21 Q2 '22 Q1 '23 Q4 '23 Q3 '24 Q2 '25

Gross Profit TTM

-7M 0 7M 14M 21M Q4 '19: 443K Q1 '20: 1.6M Q2 '20: 13.1M Q3 '20: 16M Q4 '20: 19.6M Q1 '21: 17.8M Q2 '21: 5.8M Q3 '21: 2M Q4 '21: -2.4M Q4 '19 Q2 '20 Q4 '20 Q2 '21 Q4 '21

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income TTM

-300M -200M -100M 0 100M 200M 300M Q3 '20: -268M Q4 '20: -252.5M Q1 '21: -222.4M Q2 '21: -64.8M Q3 '21: -52.1M Q4 '21: -38.9M Q1 '22: -37.8M Q2 '22: -36.6M Q3 '22: -35.2M Q4 '22: -34.3M Q1 '23: -31.5M Q2 '23: -33.5M Q3 '23: -30.4M Q4 '23: -29.3M Q1 '24: -30.8M Q2 '24: -30.8M Q3 '24: -37.7M Q4 '24: -43.6M Q1 '25: -45.5M Q2 '25: -42.6M Q4 '20 Q3 '21 Q2 '22 Q1 '23 Q4 '23 Q3 '24 Q2 '25

Net Income TTM

-270M -180M -90M 0 90M 180M 270M Q3 '20: -253.9M Q4 '20: -255.6M Q1 '21: -235.9M Q2 '21: -88.4M Q3 '21: -84.9M Q4 '21: -73.3M Q1 '22: -48.1M Q2 '22: -36.7M Q3 '22: -24.8M Q4 '22: -23.2M Q1 '23: -33.5M Q2 '23: -35.1M Q3 '23: -32.2M Q4 '23: -28.5M Q1 '24: -29.1M Q2 '24: -28.4M Q3 '24: -34M Q4 '24: -39.8M Q1 '25: -42.2M Q2 '25: -38.5M Q4 '20 Q3 '21 Q2 '22 Q1 '23 Q4 '23 Q3 '24 Q2 '25

Cost of Revenue TTM

0 100M 200M 300M Q4 '19: 58.8M Q1 '20: 84.2M Q2 '20: 243.7M Q3 '20: 247.3M Q4 '20: 272.1M Q1 '21: 231.1M Q2 '21: 53M Q3 '21: 27.3M Q4 '21: 3.3M Q4 '19 Q2 '20 Q4 '20 Q2 '21 Q4 '21

Operating Cash Flow TTM

-150M -100M -50M 0 50M 100M 150M Q3 '20: -134M Q4 '20: -137.1M Q1 '21: -97.4M Q2 '21: -77.8M Q3 '21: -71.7M Q4 '21: -56.4M Q1 '22: -52.9M Q2 '22: -44.8M Q3 '22: -34.4M Q4 '22: -29.2M Q1 '23: -25.6M Q2 '23: -27M Q3 '23: -25M Q4 '23: -25.3M Q1 '24: -27.8M Q2 '24: -26.8M Q3 '24: -30.1M Q4 '24: -34M Q1 '25: -37.5M Q2 '25: -39.8M Q4 '20 Q3 '21 Q2 '22 Q1 '23 Q4 '23 Q3 '24 Q2 '25

Free Cash Flow TTM

-150M -100M -50M 0 50M 100M 150M Q3 '19: -85M Q4 '19: -74.5M Q1 '20: -109.9M Q2 '20: -132.8M Q3 '20: -134.3M Q4 '20: -137.2M Q1 '21: -97.5M Q2 '21: -77.8M Q3 '21: -71.7M Q4 '21: -56.4M Q4 '19 Q2 '20 Q4 '20 Q2 '21 Q4 '21

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 20M 40M 60M Q2 '20: 34.7M Q3 '20: 41.9M Q1 '21: 48.9M Q2 '21: 51.4M Q3 '21: 52M Q1 '22: 3.1M Q2 '22: 3.2M Q3 '22: 3.2M Q1 '23: 3.3M Q2 '23: 3.3M Q3 '23: 3.3M Q1 '24: 42.6M Q2 '24: 42.6M Q3 '24: 42.6M Q1 '25: 42.7M Q2 '25: 855K Q1 '26: 42.8M Q2 '26: 858K Q1 '21 Q1 '22 Q1 '23 Q1 '24 Q1 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-30.00 -20.00 -10.00 0.00 10.00 20.00 30.00 Q3 '20: 2.54 Q4 '20: -1.08 Q1 '21: -5.29 Q2 '21: -0.85 Q3 '21: -0.67 Q4 '21: -25.64 Q1 '22: -23.71 Q2 '22: -25.95 Q3 '22: -28.48 Q4 '22: -7.16 Q1 '23: -10.41 Q2 '23: -10.87 Q3 '23: -9.94 Q4 '23: -2.78 Q1 '24: -1.19 Q2 '24: 1.68 Q3 '24: 3.40 Q4 '24: -0.94 Q1 '25: -0.99 Q2 '25: -7.50 Q4 '20 Q3 '21 Q2 '22 Q1 '23 Q4 '23 Q3 '24 Q2 '25

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.